In an attempt to find a new class of antimicrobial agents, a series of novel azetidin-2-ones 3a-e and thiazolidin-4-ones 4a-e of 2-amino-5-cyclopropyl-1,3,4-thiadiazole were synthesized. The synthesized compounds were confirmed by melting point, IR, (1) H NMR, (13) C NMR, and mass spectroscopy. The β-lactam derivative (3e) was found to be the most potent compound of the series displaying excellent antibacterial activities against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa with MIC values of 15.60, 31.50, 62.50, and 125 µg/mL, respectively, as compared to the positive control drug ampicillin. Molecular docking studies and determination of the leakage of UV260 - and UV280 -absorbing material (nucleic acid material and protein) confirmed that the synthesized compounds inhibit cell wall synthesis by inhibiting PTB (transpeptidase enzyme). Lipinski's rule and in silico ADME pharmacokinetic parameters are within the acceptable range defined for human use, thereby indicating their potential as a drug-like molecules.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ardp.201400140DOI Listing

Publication Analysis

Top Keywords

molecular docking
8
docking studies
8
synthesized compounds
8
synthesis vitro
4
vitro evaluation
4
evaluation molecular
4
studies azetidinones
4
azetidinones thiazolidinones
4
thiazolidinones 2-amino-5-cyclopropyl-134-thiadiazole
4
2-amino-5-cyclopropyl-134-thiadiazole antibacterial
4

Similar Publications

Background: Oxidative stress is strongly linked to neurodegeneration through the activation of c-Abl kinase, which arrests α-synuclein proteolysis by interacting with parkin interacting substrate (PARIS) and aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2). This activation, triggered by ataxia-telangiectasia mutated (ATM) kinase, leads to dopaminergic neuron loss and α-synuclein aggregation, a critical pathophysiological aspect of Parkinson's disease (PD). To halt PD progression, pharmacological inhibition of c-Abl kinase is essential.

View Article and Find Full Text PDF

Background: We continue to struggle with the prevention and treatment of the influenza virus. The 2009 swine flu pandemic, caused by the H1N1 strain of influenza A, resulted in numerous fatalities. The threat of influenza remains a significant concern for global health, and the development of novel drugs targeting these viruses is highly desirable.

View Article and Find Full Text PDF

Aims: This study aims to identify and evaluate promising therapeutic proteins and compounds for breast cancer treatment through a comprehensive database search and molecular docking analysis.

Background: Breast cancer (BC), primarily originating from the terminal ductal-lobular unit of the breast, is the most prevalent form of cancer globally. In 2020, an estimated 2.

View Article and Find Full Text PDF

Apatinib, a commonly used tyrosine kinase inhibitor in cancer treatment, can cause adverse reactions such as hypertension. Hypertension, in turn, can increase the risk of certain cancers. The coexistence of these diseases makes the use of combination drugs more common in clinical practice, but the potential interactions and regulatory mechanisms in these drug combinations are poorly understood.

View Article and Find Full Text PDF

Molecular docking to investigate HLA-associated idiosyncratic drug reactions.

Drug Metab Rev

January 2025

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Idiosyncratic drug reactions (IDRs) pose severe threats to patient health. Unlike conventionally dose-dependent side effects, they are unpredictable and frequently manifest as life-threatening conditions, such as severe cutaneous adverse reactions (SCARs) and drug-induced liver injury (DILI). Some HLA alleles, such as , , and , are known risk factors for adverse reactions induced by multiple drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!